Get startedLog in
    Picture of Alligator Bioscience AB logo

    ATORX — Alligator Bioscience AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Alligator Bioscience Says Alg.Apv-527 Meets Phase 1 Trial Endpoints

    Picture of Alligator Bioscience AB logoAlligator Bioscience AB
    11/11/2024 13:09
    Nov 11 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * FIRST-IN-CLASS BISPECIFIC ANTIBODY, ALG.APV-527, MEETS
IMPORTANT
TRIAL ENDPOINTS IN PHASE 1 SOLID TUMOR TRIAL
    * DATA INDICATE THAT TRIAL ENDPOINTS OF ADEQUATE EXPOSURE,
SAFETY,
TOLERABILITY AND BIOLOGICAL ACTIVITY WERE MET

Source text:  ID:nMFN7T99f7 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Alligator Bioscience AB

    See all news